TOP TEN perturbations for Q6XZF7 (Homo sapiens)

Organism: Homo sapiens
Gene: Q6XZF7
Selected probe(set): 212838_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q6XZF7 (212838_at) across 5217 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):4.5653048
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-3.8756104
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

SDF study 4 / untreated MDA Mb231 cell sample

Relative Expression (log2-ratio):-3.6305866
Number of Samples:3 / 6
Experimental SDF study 4
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control untreated MDA Mb231 cell sample
Untreated MDA Mb231 cells harvested after 6h.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):3.5040493
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

actinomycin D study 1 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):-2.9390879
Number of Samples:3 / 3
Experimental actinomycin D study 1
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code:
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):2.918868
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.9111643
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-2.7442589
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

RAF1 overexpr. study 1 (retrovirus) / control virus infected MCF7 cell sample

Relative Expression (log2-ratio):-2.7113771
Number of Samples:2 / 2
Experimental RAF1 overexpr. study 1 (retrovirus)
MCF-7 cell line stably transfected with retrovirus containing cDNA for RAF1. The following retroviral construct was used: pLNCRaf-1 contains human Raf-1 cDNA encoding an amino terminally truncated form of Raf-1 that is constitutively active, which is inserted into retroviral vector pLNCX encoding neomycin resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin.
Control control virus infected MCF7 cell sample
MCF7 cell line transfected with pZipneo retrovirus, which is an empty retroviral vector encoding neomycine resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin.

CD44s overexpr. study 1 / normal HEK-293 cell sample

Relative Expression (log2-ratio):2.6136646
Number of Samples:3 / 3
Experimental CD44s overexpr. study 1
Human embryonic kidney cell line HEK-293 transfected with pcDNA3.1(-) vector containing codon-optimized human CD44 sequence for expression.
Control normal HEK-293 cell sample
Untransfected, native human embryonic kidney cell line HEK-293 cell samples.